|
Completed
|
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 |
|
Completed
|
NCT00869089 -
Safety and Efficacy of CC-10004 for Prurigo Nodularis
|
Phase 2 |
|
Completed
|
NCT04501666 -
An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
|
Phase 3 |
|
Completed
|
NCT03181503 -
Safety and Efficacy of Nemolizumab in PN
|
Phase 2 |
|
Completed
|
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 |
|
Completed
|
NCT04944862 -
A Study of CDX-0159 in Patients With Prurigo Nodularis
|
Phase 1 |
|
Active, not recruiting
|
NCT05061693 -
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
|
Phase 2 |
|
Completed
|
NCT03546816 -
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
|
Phase 3 |
|
Recruiting
|
NCT06293053 -
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
|
Phase 3 |
|
Not yet recruiting
|
NCT06201715 -
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
|
N/A |
|
Completed
|
NCT02174419 -
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
|
Phase 2/Phase 3 |
|
Terminated
|
NCT03540160 -
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
|
Phase 3 |
|
Completed
|
NCT03816891 -
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
|
Phase 2 |
|
Recruiting
|
NCT05764161 -
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
|
Phase 3 |
|
Completed
|
NCT02196324 -
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
|
Phase 2 |
|
Recruiting
|
NCT03576287 -
Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
|
Phase 1/Phase 2 |
|
Completed
|
NCT05052983 -
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
|
Phase 3 |
|
Active, not recruiting
|
NCT04204616 -
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
|
Phase 3 |
|
Recruiting
|
NCT06213831 -
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
|
Phase 1 |
|
Not yet recruiting
|
NCT04681300 -
Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing
|
|